Shares of Evolus, Inc. (NASDAQ:EOLS - Get Free Report) gapped down prior to trading on Thursday following a weaker than expected earnings announcement. The stock had previously closed at $16.81, but opened at $15.26. Evolus shares last traded at $15.27, with a volume of 256,256 shares trading hands.
The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.09). The firm had revenue of $61.09 million during the quarter, compared to the consensus estimate of $62.81 million.
Wall Street Analysts Forecast Growth
Several research firms recently issued reports on EOLS. HC Wainwright restated a "buy" rating and issued a $27.00 price target on shares of Evolus in a research note on Thursday. Cantor Fitzgerald restated an "overweight" rating on shares of Evolus in a research note on Monday, September 16th. Barclays raised their price target on shares of Evolus from $16.00 to $20.00 and gave the stock an "overweight" rating in a research report on Friday, September 13th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $22.00 price objective on shares of Evolus in a report on Friday, September 13th.
Get Our Latest Report on EOLS
Insider Transactions at Evolus
In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm's stock in a transaction on Friday, August 30th. The stock was sold at an average price of $15.85, for a total transaction of $89,251.35. Following the sale, the chief marketing officer now owns 82,375 shares of the company's stock, valued at $1,305,643.75. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm's stock in a transaction on Friday, August 30th. The shares were sold at an average price of $15.85, for a total transaction of $89,251.35. Following the completion of the transaction, the chief marketing officer now owns 82,375 shares of the company's stock, valued at approximately $1,305,643.75. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Sandra Beaver sold 3,276 shares of Evolus stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the transaction, the chief financial officer now directly owns 148,502 shares in the company, valued at $2,224,559.96. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 6.10% of the company's stock.
Institutional Investors Weigh In On Evolus
A number of institutional investors have recently modified their holdings of EOLS. Assenagon Asset Management S.A. boosted its position in Evolus by 5,627.2% during the second quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company's stock valued at $10,276,000 after acquiring an additional 930,566 shares during the last quarter. Lord Abbett & CO. LLC bought a new stake in shares of Evolus during the 1st quarter valued at about $11,628,000. Armistice Capital LLC acquired a new stake in Evolus during the second quarter worth approximately $3,906,000. Zimmer Partners LP bought a new stake in Evolus in the first quarter worth approximately $4,200,000. Finally, BNP Paribas Financial Markets increased its holdings in Evolus by 84.2% in the first quarter. BNP Paribas Financial Markets now owns 405,931 shares of the company's stock worth $5,683,000 after purchasing an additional 185,532 shares in the last quarter. 90.69% of the stock is owned by institutional investors.
Evolus Stock Performance
The stock has a market capitalization of $901.56 million, a price-to-earnings ratio of -16.78 and a beta of 1.31. The company has a 50 day simple moving average of $16.29 and a 200-day simple moving average of $13.83. The company has a quick ratio of 2.67, a current ratio of 2.92 and a debt-to-equity ratio of 6.26.
About Evolus
(
Get Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
See Also
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
